治疗库欣病的新生长抑素类似物帕瑞肽

Pasiretide,a new kind of somatostatin analogs for treating Cushing disease

帕瑞肽是一种能与多受体结合的生长抑素类似物,与生长抑素受体sst1～3和sst5有高结合力。帕瑞肽能抑制GHI,GF-I和ACTH的分泌,提示其可能用于肢端肥大症与库欣病的治疗;而其在细胞试验中抑制神经内分泌肿瘤细胞增殖、在动物实验中显示能延长抑制激素分泌的时间以及类癌表达多个sst显示帕瑞肽在治疗类癌方面可能优于奥曲肽。目前帕瑞肽在肢端肥大症、类癌的Ⅱ期临床试验已经结束,有关库欣病方面Ⅲ期临床试验也已完成3,项试验证实其对于肢端肥大症、类癌是一种新的治疗手段,并成为治疗库欣病的新方法。

Pasireotide is a kind of somatostatin analogs which can bind with multiple receptors and especially has a high affinity with the somatostatin receptors sst1,sst2,sst3 and sst5.It inhibits release of GH,IGF-I and ACTH,suggesting a potency for the treatment of acromegaly and Cushing disease.Pasireotide inhibits proliferation of neuroendocrine tumor cells,prolongs the inhibition duration of the hormone secretion and carcinoid expressing multiple somatostatin receptors,which may have advantage in carcinoid treatment.Currently,the phraseⅡ clinical trails of pasireotide in acromegaly and carcinoid have been completed,and the phrase III in Cushing disease has been accomplished too,all of which suggest that pasireotide holds the promise as a new treatment for acromegaly and carcinoid,and the first medicine for Cushing disease.